Transmission Of Resistant Tuberculosis Research Articles

Does directly observed therapy (DOT) reduce drug resistant tuberculosis?

BackgroundDirectly observed therapy (DOT) is a widely recommended and promoted strategy to manage tuberculosis (TB), however, there is still disagreement about the role of DOT in TB control and the impact it has on reducing the acquisition and transmission of drug resistant TB. This study compares the portion of drug resistant genotype clusters, representing recent transmission, within and between communities implementing programs differing only in their directly observed therapy (DOT) practices.MethodsGenotype clusters were defined as 2 or more patient members with matching IS6110 restriction fragment length polymorphism (RFLP) and spoligotype patterns from all culture-positive tuberculosis cases diagnosed between January 1, 1995 and December 31, 2001. Logistic regression was used to compute maximum-likelihood estimates of odds ratios (ORs) and 95% confidence intervals (CIs) comparing cluster members with and without drug resistant isolates. In the universal DOT county, all patients received doses under direct observation of health department staff; whereas in selective DOT county, the majority of received patients doses under direct observation of health department staff, while some were able to self-administer doses.ResultsIsolates from 1,706 persons collected during 1,721 episodes of tuberculosis were genotyped. Cluster members from the selective DOT county were more than twice as likely than cluster members from the universal DOT county to have at least one isolate resistant to isoniazid, rifampin, and/or ethambutol (OR = 2.3, 95% CI: 1.7, 3.1). Selective DOT county isolates were nearly 5 times more likely than universal DOT county isolates to belong to clusters with at least 2 resistant isolates having identical resistance patterns (OR = 4.7, 95% CI: 2.9, 7.6).ConclusionsUniversal DOT for tuberculosis is associated with a decrease in the acquisition and transmission of resistant tuberculosis.

Epidemiology and Treatment of Multidrug Resistant Tuberculosis

Multidrug resistant tuberculosis is now thought to afflict between 1 and 2 million patients annually. Although significant regional variability in the distribution of disease has been recorded, surveillance data are limited by several factors. The true burden of disease is likely underestimated. Nevertheless, the estimated burden is substantial enough to warrant concerted action. A range of approaches is possible, but all appropriate interventions require scale-up of laboratories and early treatment with regimens containing a sufficient number of second-line drugs. Ambulatory treatment for most patients, and improved infection control, can facilitate scale-up with decreased risk of nosocomial transmission. Several obstacles have been considered to preclude worldwide scale-up of treatment, mostly attributable to inadequate human, drug, and financial resources. Further delays in scale-up, however, risk continued generation and transmission of resistant tuberculosis, as well as associated morbidity and mortality.

Surveillance of resistance to antituberculosis drugs in developing countries

Resistance to antituberculosis drugs is caused by poor management of tuberculosis control. It gives rise to treatment failure, relapse, further transmission of resistant tuberculosis, and multidrug-resistant tuberculosis. Widespread occurrence of multidrug-resistant tuberculosis would constitute a major threat to tuberculosis control in resource-poor countries. Although the impact of HIV on drug resistance is not yet fully understood, it is likely to exacerbate problems caused by drug resistance. In particular, HIV-related adverse effects of thiacetazone, together with the risks of transmission of HIV by parenteral administration of streptomycin, reduce the armamentarium available to tuberculosis control programmes in high HIV prevalence countries, and could encourage the development of resistance to the remaining drugs. While the prime need is to ensure, by good management and supervision, that resistance does not occur in the first place, surveillance of drug resistance is essential to determine the current scale and nature of the drug resistance problem, as well as to define the correct solutions.